Forecast

The analysts' average price target is €19.00 (+840.59%). The median is €19.00 (+840.59%).

Buy	6
Hold	2
Sell	1

News Go to news feed

INmune Bio applies for orphan designation and submits EMA documents for Ebstrocel

INmune Bio has filed with the EMA for orphan-drug designation and submitted materials for scientific advice ahead of an EU marketing-authorization application for Ebstrocel. Ebstrocel is a pooled, allogeneic mesenchymal stromal cell therapy derived from umbilical cord for the treatment of recessive dystrophic epidermolysis bullosa. The filings are intended to support an EU MAA planned for Q1 2027; parallel plans include a UK application in Q4 2026 and a US BLA in Q1 2027. If orphan designation is granted, regulatory incentives and up to ten years of market exclusivity could follow in the EU; Ebstrocel already has orphan status in the US. » More on de.investing.com
INmune Bio receives $4.6 million in research grants from Australia and the UK

INmune Bio has received government research and development grants totaling about $4.6 million (approximately $4.2 million from Australia and about $0.4 million from the UK). The non-dilutive funds exceed the net cash used for operating activities in the second quarter and extend the company’s cash runway. The grants relate to eligible expenditures for clinical development, manufacturing and regulatory activities. INmune Bio is advancing its CORDStrom and XPro1595 platforms; regulatory filings for CORDStrom are planned in the UK (2026), the EU (2027) and the US, while XPro1595 has received FDA fast-track status and is intended for a phase 2b/3 program in early Alzheimer’s disease. » More on de.investing.com
INmune Bio presents promising imaging data from phase 2 study of XPro

INmune Bio released imaging data from its phase 2 study of XPro/XPro1595 in early‑stage Alzheimer’s that showed a significant improvement in white‑matter myelin integrity after 24 weeks (p < 0.01). Stronger effects were observed in patients selected using the company’s proprietary biomarker enrichment. The analysis includes Chi‑Separation and Cortical Disarray Measurement, two advanced MRI techniques, and supports the idea that XPro shows relevant biological effects early. XPro1595 has FDA Fast Track status; INmune Bio is advancing a registrational phase 2b/3 program and has a market capitalization of about $45.7 million with analyst targets between $4 and $9. » More on de.investing.com

Financials

In the last quarter, INMUNEBIO INC. had revenue of €0 and net profit of -€1.12M

(EUR)	Jun 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-1.12M	94.62%
EBITDA	-1.03M	84.96%

Fundamentals

Metric	Value
Market capitalization	€56.13M
Number of shares	26.59M
52-week high/low	€2.16 - €0.94
Dividends	No
Beta	0.90
P/E ratio	-3.54
PEG ratio	-0.03
P/B ratio	3.21
P/S ratio	0.00

Company profile

INmune Bio, Inc. ist ein im klinischen Stadium befindliches Immuntherapie-Unternehmen, das sich auf die Entwicklung von Medikamenten konzentriert, die das angeborene Immunsystem des Patienten umprogrammieren, um Krankheiten zu behandeln. Das Unternehmen entwickelt und vermarktet Produktkandidaten zur Behandlung von hämatologischen Malignomen, soliden Tumoren und chronischen Entzündungen. Zu seinen Entwicklungsprogrammen gehören INKmune, das sich auf die Behandlung von Frauen mit refraktärem Ovarialkarzinom und Patienten mit myelodysplastischem Hochrisikosyndrom konzentriert, INB03, eine Immuntherapie zur Behandlung von Patienten mit hämatologischen malignen Erkrankungen und soliden Tumoren, und XPro1595 zur Behandlung der Alzheimer-Krankheit. Das Unternehmen hat Lizenzvereinbarungen mit Xencor, Inc, Immune Ventures, LLC, der University of Pittsburg und dem University College London abgeschlossen. INmune Bio, Inc. wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Boca Raton, Florida.

Name	INMUNEBIO INC.
CEO	David J. Moss
Headquarters	Boca Raton, fl USA
Website	inmunebio.com
Sector	Consumer Staples
Industry	Food Products
IPO	02/04/2019
Employees	21